- Synergistic collaboration to revolutionize age-related therapies worldwide
- Deal valued at over
$300 million USD for initial product
The agreement, potentially exceeding
A New Frontier in Age-Related Therapies
Products resulting from this collaboration will utilize Turn Bio's Epigenetic Reprogramming of Age (ERATM) technology and its novel eTurna™ delivery platform. These cutting-edge technologies aim to restore optimal gene expression, combatting the effects of aging at the cellular level to treat and potentially cure chronic conditions.
"This partnership is a milestone for Turn Bio," said company CEO
HanAll has closely monitored Turn Bio's progress since its initial investment, recognizing the revolutionary potential of its epigenetic reprogramming technology.
"Turn Bio's innovative approach to epigenetic reprogramming aligns closely with HanAll's mission to explore innovative medicines to expand our therapeutic area," said
Expanding Horizons in Regenerative Medicine
The partnership expands Turn Bio's development, which had primarily focused on dermatology and immunology, to two other organs most commonly affected by age-related conditions. This means Turn Bio is working on therapies to treat and potentially cure most diseases caused by aging.
"The power of ERA™ technology is that it can rejuvenate cells in virtually any organ in the body," said Turn Bio Co-founder
ABOUT TURN BIOTECHNOLOGIES
Turn Bio is a pre-clinical-stage company focused on repairing tissue at the cellular level and developing transformative drug delivery systems. The company's proprietary mRNA-based ERA™ reprogramming technology aims to restore optimal gene expression by combatting the effects of aging in the epigenome. This potentially restores cells' ability to prevent or treat disease and heal or regenerate tissue and helps to fight incurable chronic diseases. Its eTurna™ delivery platform uses unique formulations to precisely deliver cargo to specific organs, tissues, and cell types.
The company is completing pre-clinical research on tailored therapies targeting indications in dermatology and immunology, and developing therapies for ophthalmology, osteo-arthritis, and the muscular system. For more information, see www.turn.bio.
About
HanAll has also expanded its focus to immunology, oncology, neurology, and ophthalmology to discover and develop innovative medicines for patients with diseases for which there are no effective treatments. One of its lead pipeline asset, HL161 (INN: batoclimab), an anti-FcRn antibody, is being developed in Phase 3 and Phase 2 trials across the world for the treatment of autoimmune diseases including generalized myasthenia gravis (gMG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP), and Graves' disease (GD). Another lead asset, HL036 (INN: tanfanercept), a TNF inhibitor protein, is being evaluated in Phase 3 clinical studies in the US and is also being evaluated in
FOR MORE INFORMATION, CONTACT:
jim@rightstorygroup.com or (312) 543-9026
View original content to download multimedia:https://www.prnewswire.com/news-releases/turn-biotechnologies-signs-global-licensing-agreement-with-hanall-biopharma-to-develop-eye-and-ear-therapies-302156392.html
SOURCE
© Canada Newswire, source